Feasibility and Planning Studies for Development of Specialized Programs of Research Excellence (SPOREs) to Investigate Cancer Health Disparities (P20 Clinical Trial Optional)

Funding Agency:
National Institutes of Health

This Funding Opportunity Announcement (FOA) invites applications for development of translational research programs that are focused upon investigating cancer health disparities. The P20 grants will support feasibility and planning activities to build comprehensive cancer health disparities research programs. It is the expectation that the research programs developed by the P20 awards should be competitive with other applications for a full Specialized Programs of Research Excellence (SPORE), addressing cancer health disparities as a cross-cutting research theme.

All applications must propose translational research that will contribute to improved prevention, early detection, diagnosis, and/or treatment of cancers found to disproportionately affect specific racial/ethnic minority populations. Furthermore, all research projects must be focused upon knowledge of human biology with a translational human endpoint proposed.

All the proposed P20 programs must include a minimum of two well-developed translational research projects, as well as contribute significantly to the development of specialized shared resources core facilities, improved research model systems, and collaborative research activities with other institutions, P20 awardees, and/or current SPORE grantees.


  • Letter of Intent Due Date: 30 days prior to the application due date
  • Application Due Date(s): June 19, 2019, October 18, 2019, June 19, 2020, and October 18, 2020

RFA-CA-19-034 Expiration Date October 19, 2020

Agency Website

Eligibility Requirements

Investigators who are designated as PDs/PIs on an active SPORE grant or on a pending SPORE application cannot be designated as PD/PI on this P20 application.



Amount Description

Applicants may request a maximum of $800,000 direct costs per year.

The maximum project period is 3 years.

Funding Type





Medical - Translational

External Deadline

October 18, 2020